Patents Assigned to Alere San Diego, Inc.
-
Publication number: 20140099674Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further disclosed are conditions to enable real-time monitoring of RPA reactions, methods to regulate RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes.Type: ApplicationFiled: March 27, 2013Publication date: April 10, 2014Applicant: Alere San Diego Inc.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
-
Patent number: 8637253Abstract: The present invention features novel, diverse, hybrid and engineered recombinase enzymes, and the utility of such proteins with associated recombination factors for carrying out DNA amplification assays. The present invention also features different recombinase ‘systems’ having distinct biochemical activities in DNA amplification assays, and differing requirements for loading factors, single-stranded DNA binding proteins (SSBs), and the quantity of crowding agent employed.Type: GrantFiled: November 30, 2011Date of Patent: January 28, 2014Assignee: Alere San Diego, Inc.Inventors: Olaf Piepenburg, Niall A. Armes, Mathew James David Parker
-
Patent number: 8580507Abstract: This disclosure provides for methods and reagents for rapid multiplex RPA reactions and improved methods for detection of multiplex RPA reaction products. In addition, the disclosure provides new methods for eliminating carryover contamination between RPA processes.Type: GrantFiled: July 6, 2011Date of Patent: November 12, 2013Assignee: Alere San Diego, Inc.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes
-
Patent number: 8574846Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundres of megabases in length.Type: GrantFiled: August 4, 2011Date of Patent: November 5, 2013Assignee: Alere San Diego, Inc.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
-
Patent number: 8524462Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.Type: GrantFiled: November 14, 2007Date of Patent: September 3, 2013Assignee: Alere San Diego, Inc.Inventors: Gunars Valkirs, Paul H. McPherson
-
Patent number: 8460875Abstract: This disclosure provides methods for Recombinase-Polymerase Amplification (RPA) of a target DNA. The methods exploit the properties of the bacterial RecA and related proteins to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the methods allow amplification of DNA up to hundreds of megabases in length.Type: GrantFiled: July 28, 2011Date of Patent: June 11, 2013Assignee: Alere San Diego, Inc.Inventors: Niall A. Armes, Derek L. Stemple
-
Patent number: 8426134Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further disclosed are conditions to enable real-time monitoring of RPA reactions, methods to regulate RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes.Type: GrantFiled: August 18, 2011Date of Patent: April 23, 2013Assignee: Alere San Diego, Inc.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
-
Publication number: 20130059290Abstract: A method includes contacting a crude matrix with components of an isothermal nucleic acid amplification reaction for a target nucleic acid species, thereby providing a mixture; incubating the mixture under conditions sufficient for the isothermal nucleic acid amplification reaction to proceed, thereby providing a product; and determining whether an indicator of the target nucleic acid species is present in the product.Type: ApplicationFiled: September 24, 2010Publication date: March 7, 2013Applicant: Alere San Diego, Inc.Inventor: Niall A. Armes
-
Publication number: 20130045475Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: October 23, 2012Publication date: February 21, 2013Applicant: ALERE SAN DIEGO, INC.Inventor: Alere San Diego, Inc.
-
Patent number: 8299226Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: GrantFiled: August 10, 2011Date of Patent: October 30, 2012Assignee: Alere San Diego, Inc.Inventors: Olaf Piepenburg, Derek L. Stemple, Niall A. Armes
-
Publication number: 20120258499Abstract: The present invention features novel, diverse, hybrid and engineered recombinase enzymes, and the utility of such proteins with associated recombination factors for carrying out DNA amplification assays. The present invention also features different recombinase ‘systems’ having distinct biochemical activities in DNA amplification assays, and differing requirements for loading factors, single-stranded DNA binding proteins (SSBs), and the quantity of crowding agent employed.Type: ApplicationFiled: November 30, 2011Publication date: October 11, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Niall A. Armes, Mathew James David Parker
-
Publication number: 20120258456Abstract: A process includes providing a mixture that includes a recombinase, a single-strand binding protein, and one or more oligonucleotides; and detecting particles in the reaction mixture.Type: ApplicationFiled: April 6, 2012Publication date: October 11, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Niall A. Armes, Olaf Piepenburg, Catherine Jean Greenwood
-
Patent number: 8283128Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.Type: GrantFiled: June 2, 2011Date of Patent: October 9, 2012Assignee: Alere San Diego, Inc.Inventors: Gunars Valkirs, Paul H. McPherson
-
Publication number: 20120129173Abstract: This disclosure describes kits, reagents and methods for Recombinase Polymerase Amplification (RPA) of a target DNA that exploit the properties of re-combinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed kits, reagents and methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods.Type: ApplicationFiled: June 7, 2010Publication date: May 24, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Niall A. Armes
-
Publication number: 20120129198Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma. Also disclosed are antibodies which recognize, unbound troponin forms, the forms of troponin in binary complexes, the ternary complex of troponin I, T and C, and the conformations of troponin I having intramolecularly oxidized and reduced cysteines.Type: ApplicationFiled: November 16, 2011Publication date: May 24, 2012Applicant: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Publication number: 20120082990Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundres of megabases in length.Type: ApplicationFiled: August 4, 2011Publication date: April 5, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
-
Publication number: 20120058517Abstract: This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further disclosed are conditions to enable real-time monitoring of RPA reactions, methods to regulate RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carry-over contamination, and methods to employ sequence-specific third ‘specificity’ probes.Type: ApplicationFiled: August 18, 2011Publication date: March 8, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Colin H. Williams, Niall A. Armes, Derek L. Stemple
-
Publication number: 20120040345Abstract: This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided.Type: ApplicationFiled: August 10, 2011Publication date: February 16, 2012Applicant: ALERE SAN DIEGO, INC.Inventors: Olaf Piepenburg, Derek L. Stemple, Niall A. Armes
-
Patent number: 8114612Abstract: Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction are disclosed. Troponin I and T exist in various conformations and the ratios of monomeric troponin I and T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed are systems to determine the presence of a troponin form or a group of troponin forms in whole blood, serum or plasma samples. Disclosed is a method for improving the recovery of troponin I or T from a surface used in immunoassays. Also disclosed are antibodies which recognize unbound troponin forms, the forms of troponin in binary complexes, the ternary complex of troponin I, T and C, and the conformations of troponin I having intramolecularly oxidized and reduced cysteines.Type: GrantFiled: January 7, 2011Date of Patent: February 14, 2012Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson
-
Patent number: 8084224Abstract: A method to facilitate recovery troponin I and/or troponin T from a sample comprising addition of troponin C to the sample or to a surface from which the troponin I and/or troponin T are recovered.Type: GrantFiled: April 5, 2010Date of Patent: December 27, 2011Assignee: Alere San Diego, Inc.Inventors: Kenneth F. Buechler, Paul H. McPherson